KRAS and ovarian serous adenocarcinoma: found that combining FAKi with the RAFi/MEKi avutometinib significantly reduced tumor growth in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated non-small cell lung cancer (NSCLC) and low-grade serous ovarian cancer (LGSOC), respectively, using cell line-derived xenografts and patient-derived xenografts in mice.12